Pacific Biosciences Of California (PACB) Share-based Compensation Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Pacific Biosciences Of California | 481.66 Mn | 205.70 Mn | 12.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.19% |
| Dec 31, 2025 | 12.69% |
| Sep 30, 2025 | 17.08% |
| Jun 30, 2025 | 29.76% |
| Mar 31, 2025 | 17.94% |
| Dec 31, 2024 | 32.89% |
| Sep 30, 2024 | 35.07% |
| Jun 30, 2024 | 33.31% |
| Mar 31, 2024 | 34.84% |
| Dec 31, 2023 | 17.13% |
| Sep 30, 2023 | 30.89% |
| Jun 30, 2023 | 27.92% |
| Mar 31, 2023 | 27.72% |
| Dec 31, 2022 | 27.21% |
| Sep 30, 2022 | 30.68% |
| Jun 30, 2022 | 30.58% |
| Mar 31, 2022 | 35.43% |
| Dec 31, 2021 | 31.39% |
| Sep 20, 2021 | 29.91% |
| Jun 30, 2021 | 25.69% |
| Mar 31, 2021 | 17.28% |
| Dec 31, 2020 | 5.55% |
| Sep 30, 2020 | 9.04% |
| Jun 30, 2020 | -0.52% |
| Mar 31, 2020 | 4.37% |
| Dec 31, 2019 | 5.23% |
| Sep 30, 2019 | 10.62% |
| Jun 30, 2019 | 12.97% |
| Mar 31, 2019 | 14.05% |
| Dec 31, 2018 | 24.21% |
| Sep 30, 2018 | 18.74% |
| Jun 30, 2018 | 16.41% |
| Mar 31, 2018 | 13.98% |
| Dec 31, 2017 | 16.17% |
| Sep 30, 2017 | 15.78% |
| Jun 30, 2017 | 14.16% |
| Mar 31, 2017 | 17.91% |
| Dec 31, 2016 | 8.05% |
| Sep 30, 2016 | 11.31% |
| Jun 30, 2016 | 10.87% |
| Mar 31, 2016 | 8.10% |
| Dec 31, 2015 | 3.31% |
| Sep 30, 2015 | 7.43% |